CL
CRSP icon

Choreo LLC’s CRISPR Therapeutics CRSP Stock Holding History

Choreo LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$398K Buy
7,292
+178
+3% +$9.38K ﹤0.01% 1139
2026
Q1 		$338K Sell
7,114
-975
-12% -$51.4K ﹤0.01% 1176
2025
Q4 		$430K Buy
8,089
+443
+6% +$26.5K 0.01% 996
2025
Q3 		$496K Buy
7,646
+1,631
+27% +$93.6K 0.01% 930
2025
Q2 		$293K Buy
+6,015
New +$233K ﹤0.01% 1193
2024
Q3 		– Sell
-4,047
Closed -$218K – 1640
2024
Q2 		$218K Buy
+4,047
New +$234K ﹤0.01% 1287

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Choreo LLC's CRSP Position: Q2 2026 in Review

Choreo LLC increased its CRISPR Therapeutics (CRSP) stake by 2.5% in Q2 2026, buying an estimated $9.38K and bringing the position to 7,292 shares worth $398K. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

Choreo LLC first reported a position in CRSP in Q2 2024 and has held it in 6 quarters since. The position peaked at $496K in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Choreo LLC held 7,292 shares of CRISPR Therapeutics worth $398K as of Q2 2026.
  • Choreo LLC bought 178 CRISPR Therapeutics shares in Q2 2026, an estimated $9.38K.
  • CRISPR Therapeutics made up ﹤0.01% of Choreo LLC's portfolio in Q2 2026, its #1139 holding.
  • Choreo LLC first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Choreo LLC's CRISPR Therapeutics position peaked at $496K in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Choreo LLC's 13F filing for Q2 2026, filed 4 Aug 2026.